



Wang, Huiping; Kong, Fanrong; Sorrell, Tania C.; Wang, B.; McNicholas, Paul; Pantarat, Namfon; Ellis, 
David Hedley; Xiao, Meng; Widmer, F.; Chen, S.  
Rapid detection of ERG11 gene mutations in clinical Candida albicans isolates with reduced susceptibility 
to fluconazole by rolling circle amplification and DNA sequencing, BMC Microbiology, 2009; 9:167 
 
© 2009 Wang et al.; licensee BioMed Central Ltd.  
This is an open access article distributed under the terms of the Creative Commons Attribution License 
(http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction 
in any medium, provided the original work is properly cited.  


























Anyone is free: 
• to copy, distribute, and display the work; 
• to make derivative works; 
• to make commercial use of the work; 
Under the following conditions: Attribution 
• the original author must be given credit; 
• for any reuse or distribution, it must be made clear to others what the license terms of this work 
are; 




10th December 2012 
BioMed Central
ss
BMC MicrobiologyOpen AcceResearch article
Rapid detection of ERG11 gene mutations in clinical Candida 
albicans isolates with reduced susceptibility to fluconazole by rolling 
circle amplification and DNA sequencing
Huiping Wang†1, Fanrong Kong†2, Tania C Sorrell2, Bin Wang3, 
Paul McNicholas4, Namfon Pantarat2, David Ellis5, Meng Xiao6, 
Fred Widmer2 and Sharon CA Chen*2
Address: 1Department of Dermatology, Tianjin Medical University General Hospital, Tianjin Medical University, Tianjin, PR China, 2Centre for 
Infectious Diseases and Microbiology, The University of Sydney, Westmead Hospital, Sydney, Australia, 3Retroviral Genetics Laboratory, Centre 
for Virus Research, Westmead Millennium Institute and the University of Sydney, Sydney, Australia, 4Schering-Plough Research Institute, 
Kenilworth, New Jersey, USA, 5Mycology Unit, Women's and Children's Hospital, Adelaide, Australia and 6Life Science College, Peking University, 
Beijing, PR China
Email: Huiping Wang - huiping1208@163.com; Fanrong Kong - fanrong.kong@swahs.health.nsw.gov.au; 
Tania C Sorrell - tsorrell@usyd.edu.au; Bin Wang - bin_wang@wmi.usyd.edu.au; Paul McNicholas - paul.mcnicholas@spcorp.com; 
Namfon Pantarat - namfon.pantarat@swahs.health.nsw.gov.au; David Ellis - deelis@adelaide.edu.au; 
Meng Xiao - cjtcxiaomeng@yahoo.com.cn; Fred Widmer - fred.widmer@swahs.health.nsw.gov.au; 
Sharon CA Chen* - sharon.chen@swahs.health.nsw.gov.au
* Corresponding author    †Equal contributors
Abstract
Background: Amino acid substitutions in the target enzyme Erg11p of azole antifungals contribute
to clinically-relevant azole resistance in Candida albicans. A simple molecular method for rapid
detection of ERG11 gene mutations would be an advantage as a screening tool to identify
potentially-resistant strains and to track their movement. To complement DNA sequencing, we
developed a padlock probe and rolling circle amplification (RCA)-based method to detect a series
of mutations in the C. albicans ERG11 gene using "reference" azole-resistant isolates with known
mutations. The method was then used to estimate the frequency of ERG11 mutations and their type
in 25 Australian clinical C. albicans isolates with reduced susceptibility to fluconazole and in 23
fluconazole-susceptible isolates. RCA results were compared DNA sequencing.
Results: The RCA assay correctly identified all ERG11 mutations in eight "reference" C. albicans
isolates. When applied to 48 test strains, the RCA method showed 100% agreement with DNA
sequencing where an ERG11 mutation-specific probe was used. Of 20 different missense mutations
detected by sequencing in 24 of 25 (96%) isolates with reduced fluconazole susceptibility, 16 were
detected by RCA. Five missense mutations were detected by both methods in 18 of 23 (78%)
fluconazole-susceptible strains. DNA sequencing revealed that mutations in non-susceptible
isolates were all due to homozygous nucleotide changes. With the exception of the mutations
leading to amino acid substitution E266D, those in fluconazole-susceptible strains were
heterozygous. Amino acid substitutions common to both sets of isolates were D116E, E266D,
K128T, V437I and V488I. Substitutions unique to isolates with reduced fluconazole susceptibility
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BMC Microbiology 2009, 9:167 http://www.biomedcentral.com/1471-2180/9/167were G464 S (n = 4 isolates), G448E (n = 3), G307S (n = 3), K143R (n = 3) and Y123H, S405F and
R467K (each n = 1). DNA sequencing revealed a novel substitution, G450V, in one isolate.
Conclusion: The sensitive RCA assay described here is a simple, robust and rapid (2 h) method
for the detection of ERG11 polymorphisms. It showed excellent concordance with ERG11
sequencing and is a potentially valuable tool to track the emergence and spread of azole-resistant
C. albicans and to study the epidemiology of ERG11 mutations. The RCA method is applicable to
the study of azole resistance in other fungi.
Background
Candida albicans causes systemic infections, typically in
immunocompromised patients, as well as mucosal infec-
tions such as oropharyngeal candidiasis (OPC) in HIV-
infected patients and chronic vaginal infections [1,2].
Azole antifungal drugs are the mainstay of management
of such infections. However, with increased use of these
agents, particularly fluconazole, treatment failures associ-
ated with the emergence of azole-resistant strains of C.
albicans have occurred [3-6] This has been most evident in
HIV/AIDS patients receiving long-term therapy for OPC
[3,7]
The azoles bind to and inhibit the activity of lanosterol
14α-demethylase (Erg11p), a key enzyme in the fungal
ergosterol biosynthesis pathway [8]. Several mechanisms
of resistance to azoles have been described in C. albicans.
These include increased expression of the drug efflux
pump genes such as MDR1, CDR1 and CDR2 [3,9-11],
amino acid substitutions in the target enzyme Erg11p due
to missense mutations in the ERG11 gene [3,5,10,12-15]
and possibly, overexpression of ERG11 [3,16] Impor-
tantly in any one isolate, resistance may be due to a com-
bination of mechanisms [3-5,15].
To date, more than 60 amino acid substitutions have been
described in Erg11p with at least 30 of these identified in
azole-resistant isolates [5,12,14-17] The impact of indi-
vidual substitutions, however, varies, and may differ
between azoles. For example, substitutions such as
Y132H, G450E, G464S, R467K and S405F appear to pri-
marily impact on fluconazole and voriconazole, but not
posaconazole, susceptibility [12,13,16,17] The effect of
substitutions can also be additive – strains with G129A
and G464S substitutions display higher MICs azoles com-
pared with those with the G129A substitution alone [18].
The contributions of yet other ERG11 mutations to resist-
ance are uncertain [15,19]. As most strains of C. albicans
are diploid, nucleotide mutations may occur as
homozygous (in both alleles) or as heterozygous (in one
allele) substitutions; the association of either type of
mutation with the resistant (or susceptible) phenotype is
not well defined [3,20].
Nonetheless, since even single nucleotide polymorphisms
(SNPs) in the ERG11 gene can have an impact on suscep-
tibility and contribute to resistance [5,13,15,18,19,21],
the documentation of these changes is important. To date,
the frequency and clinical relevance of specific mutations
in unselected azole-resistant isolates is poorly-defined
[17] although in one survey, ERG11 mutations contrib-
uted to resistance in 65% of fluconazole-resistant C. albi-
cans from HIV patients with OPC [5]. In clinical practice,
detection of ERG11 mutations as potential markers or co-
markers of resistance would assist both the identification
and tracking of azole-resistant strains. Traditionally, DNA
sequence analysis has been the standard for identifying
ERG11 nucleotide changes [5,14,17,19] However, circu-
larisable or padlock probes have recently been shown to
reliably detect SNPs with high specificity, offering a rapid
simple alternative to sequencing [22,23]. Padlock probes
comprise three distinct regions: a central linker is flanked
by sequences complementary to the 5' and 3' termini of
the target sequence. Upon hybridisation to the target, the
probe ends are brought together and are joined by DNA
ligase to form a closed circular molecule in a highly target-
dependent manner (Figure 1). The intensity of the probe
signal is then increased exponentially by rolling circle
amplification (RCA) generating up to a 109-fold signal
amplification within 90 min [22-24] RCA-based assays
have been successfully used to identify fungal pathogens
[25,26] but have not yet been applied to the detection of
gene mutations associated with antifungal drug resist-
ance.
The present report describes the development and valida-
tion of a sensitive RCA-based SNP detection assay using
real time PCR to detect point mutations in the C. albicans
ERG11 gene in eight azole-resistant "reference" isolates
with known mutations [15]; ERG11 was chosen as the tar-
get gene to detect SNPs associated with azole resistance in
a proof of principle study. In the study, RCA and DNA
sequencing were applied to estimate the frequency of a
series of ERG11 mutations and their nature in 25 unse-
lected Australian C. albicans clinical isolates with reduced
susceptibility to fluconazole. The results were compared
with those obtained for 23 fluconazole-susceptible
strains.Page 2 of 12
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C. albicans isolates and azole susceptibilities
Thirty-three isolates had reduced susceptibility to flucona-
zole. Twenty-eight were recovered from the oropharynx,
two from the vagina and one each from bile, sputum and
blood (Tables 1 and 2). The ERG11 gene from eight of
these isolates, referred to as "reference" isolates, was pre-
viously sequenced (see Methods and Table 1) [15]; the
remaining 25 clinical isolates were interrogated for ERG11
mutations (Table 2). An additional 23 fluconazole-sus-
ceptible isolates (see Methods for categories of suscepti-
bility/resistance) cultured from a range of body sites
(Table 2) were studied. Thus 48 "test" isolates were ana-
lysed by RCA and DNA sequencing.
One of the eight "reference" isolates was susceptible-dose
dependent (S-DD; MIC 16–32 μg/ml) to fluconazole and
seven were fluconazole-resistant (MIC ≥ 64 μg/ml; Table
Typical design of a circularisable padlock probeFigure 1
Typical design of a circularisable padlock probe. Design and components of a typical padlock probe as exemplified by 
the Ca-Y132H probe specific for the Y132H amino acid substitution. The probe comprises (i) a 5'-phosphorylated end; (ii) a 
"backbone" containing binding sites for the RCA primers (RCA primer 1 and 2, respectively) designated by bold upper case let-
ters) as well as the non-specific linker regions (designated by bold lower case letters) and (iii) a 3'-end. The 5'- and 3'-ends of 
the probe are complementary to the 5' and 3' termini of the target sequence in reverse, in this example, to the C. albicans 
sequence (GenBank accession no. AF153844). Abbreviations: 5'-P, 5'-phosphorylated binding arm; 3'-, 3' binding arm.










1 C438 Oropharynx 128 2 Y257H, G464S Y257H, G464S
C440 Oropharynx >256 >16 A61V, Y257H, G307S, G464S A61V, Y257H, G307S, G464S
2 C470 Oropharynx 32 0.25 S405F S405F
3 C480 Oropharynx 128 8 G464S, K128T, R467I G464S, K128T, R467I
4 C507 Oropharynx 64 8 G464S, H283R, Y132H G464S, H283R, Y132H
5 C527 Oropharynx 256 4 G450E, Y132H G450E, Y132H
6 C577 Oropharynx 128 0.5 G464S G464S
7 C594 Oropharynx 128 16 S405F, Y132H S405F, Y132H
a Abbreviations: RCA, rolling circle amplification; FLU, fluconazole; VOR, voriconazole.
b Chau et al. [15].Page 3 of 12
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Table 2: MIC results and Erg11p substitutions for 25 C. albicans isolates with reduced susceptibility to fluconazole and 23 fluconazole-
susceptible isolates by RCAa and ERG11 sequencing.
MIC (μg/ml) Erg 11p amino acid substitutions
D D E F F G G G G K K R S V V Y
1 2 2 1 4 3 4 4 4 1 1 4 4 4 4 1
Patient/isolate no. Site FLUa VORa 1 7 6 4 4 0 4 6 6 2 4 6 0 3 8 3
6 8 6 5 9 7 8 4 5 8 3 7 5 7 8 2
E E D L S S E S S T R K F I I H
Isolates with reduced fluconazole susceptibility
1b Oropharynx 16 0.25 + + +
2b Vagina >256 0.03
3-Ab, c Oropharynx 16 0.25 + + +
- Bb, c Oropharynx 16 0.5 + + +
4d Oropharynx 256 0.25 + + +
5d Oropharynx 256 0.125 +
6-Ac, d Oropharynx 256 >16 +
-Bc, d Oropharynx 256 >16 +
7d Oropharynx 256 >16 + + + +
8-Ac, d Oropharynx 256 0.5 + + +
-Bc, d Oropharynx 256 1 + + +
9d Oropharynx 256 >16 + +
10d Oropharynx 256 2 + + + +
11d Oropharynx 256 0.008 + +
12-Ac, d Oropharynx 256 2 +
-Bc, d Sputum 32 0.5 + + +
13d Vagina 32 0.016 +
14d Blood 256 >16 + +
15d Bile 256 16 +
16-Ac, d Oropharynx 16 0.125 + + +
-Bc Oropharynx 256 2 + + + +
-Cc, d Oropharynx 256 16 + + + + +
17d Oropharynx 64 0.5 +
18d Oropharynx 128 2 + + +
19d Oropharynx 256 0.5 + + +
Fluconazole-susceptible isolatesb
ATCC 10231 UNa 0.125 0.008
ATCC 90028 Blood 025 0.03
20 Blood 0.25 <0.008 + +
21 Oropharynx 0.12 0.008 + +
22 Blood 0.5 0.016
23 Blood 0.5 0.016
24 Blood 0.25 0.008
25 Blood 0.25 0.008 + +
26 Blood 0.5 0.008 + +
27 Blood 0.5 0.008 + +
28 Blood 0.25 <0.008 + +
29 Skin 1 0.016 + +
30 Peritoneal fluid 1 2 + +
31 Blood 0.12 0.125 + + +
32 Blood 0.125 0.008 + +
33 Blood 0.5 0.008 + + +
34 Tissue 0.25 0.008 + +
35 Blood 2 0.008 + +
36 Blood 0.25 0.016 + +
37 Liver 0.5 <0.008 + +
38 Blood 0.25 <0.008 + + +
39 Blood 0.125 <0.008 +
40 Bone 0.25 <0.008 + +
The "+" sign denotes the presence of the mutation.
aAbbreviations: RCA, rolling circle amplification; FLU, fluconazole; VOR, voriconazole; UN, unknown.
b Isolates from the Centre for Infectious Diseases and Microbiology, Westmead Hospital, Sydney.
c The "A" and "B" notation of patient numbers refers to isolates cultured sequentially from the same patient at different times.
dIsolates obtained from the Mycology Unit, Women's and Children's Hospital, Adelaide.
BMC Microbiology 2009, 9:167 http://www.biomedcentral.com/1471-2180/9/1671); five of these seven were also resistant to voriconazole
(MIC ≥ 4 μg/ml) [15,27]. Six of the 25 Australian isolates
(from patients 1, 3, 12, 13 and 16; Table 2) had flucona-
zole MICs in the S-DD range and were susceptible to vor-
iconazole; the remaining 19 were resistant to fluconazole
and seven (from patients 6, 7, 9, 14, 15 and 16) of these
were cross-resistant to voriconazole (Table 2). All 23 flu-
conazole-susceptible isolates were also susceptible to vor-
iconazole (Table 2).
Detection of ERG11 mutations by RCA: Sensitivity and 
specificity
Point mutation-specific RCA probes were designed based
on the target polymorphism site of interest in the ERG11
gene (see Additional file 1). To assess the sensitivity of the
RCA-based assay, RCA was initially performed on 10-fold
serial dilutions of the target template (PCR product; see
Methods) ranging from 1011 to 100 copies of template. For
all isolates studied, a clear RCA fluorescence signal was
observed with a sensitivity of detection of 109 copies;
below this copy number, the signal was not easily distin-
guishable from the background signal (as defined when
amplifying target template that did not have the mutation
of interest) (Figure 2). Only signals that were clearly meas-
urable above background were considered to be indicative
of the presence of the mutation.
The capability of the RCA assay to detect heterozygous, as
well as homozygous ERG11 nucleotide changes was
assessed indirectly by testing its ability to detect a specific
mutation in the presence of wild-type template (ie. tem-
plate without the mutation of interest) using the eight
"reference" isolates. For each of the known ERG11 muta-
tions (Table 1), target template (1011 copies) containing
the mutation at 100%, 50%, 20%, 10%, 5%, 2% and 0%
concentration in a backdrop of wild-type template were
prepared by mixing both templates at the above-men-
tioned ratios. In all cases, a clear RCA signal above back-
ground was observed down to a dilution containing 5%
target template (Figure 3); results were reproducible with
minimal or no variation in repeat (n = 3) experiments.
The results demonstrate that the RCA assay was able to
detect ERG11 mutations with high sensitivity in the pres-
ence of mixtures of DNA and that the sensitivity was well
Sensitivity of the RCA assayFigure 2
Sensitivity of the RCA assay. RCA was performed on 10-fold serial dilutions of the target template ranging from 1011 to 100 
copies of target template (PCR product). The figure illustrates the RCA reaction using the Ca-Y132H-specific probe to detect 
1011, 1010 and 109 copies of the template containing the Y132H mutation (obtained from amplifying DNA from isolate C594). 
RCA signals are shown as exponential increases in florescence signal above baseline (indicated by the "negative signal" label and 
defined as the signal obtained when amplifying target template that did not have the mutation of interest). The intensity of the 
signal weakened with decreasing copy numbers starting at 1011copies and the sensitivity of the assay corresponded to a con-
centration of 109copies of target template.Page 5 of 12
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changes (expected ratio of target template (with muta-
tion) to template without mutation of 1:1)).
The RCA assay was also highly specific. Amplification of
probe signals was seen only with matched template-probe
mixtures. No signal was seen when template from isolates
that did not contain the ERG11 polymorphism targeted
by a specific padlock probe were used. Figure 4 illustrates
a typical padlock probe-RCA reaction using a probe to
detect the Erg11p Y132H mutation. For isolates C507,
C527 and C594 (Table 1), exponential increases in fluo-
rescence signals were readily interpretable, indicating the
presence of the Y132H mutation. Other "reference" iso-
lates produced a signal at "background" level, indicative
of absence of the mutation. All 10 known ERG11 muta-
tions in the "reference" isolates were correctly identified.
The duration of the RCA procedure was 2 h; however, a
readily discernible signal was usually evident 15 min after
commencement of the RCA reaction.
Investigation of ERG11 mutations in test isolates by RCA 
and ERG11 sequencing
The ERG11 gene for each of the 48 test isolates (25 non-
fluconazole susceptible and 23 fluconazole-susceptible)
was amplified by PCR and a 1370 bp fragment (nt 131–
1500) was probed using RCA or subject to DNA sequenc-
ing (Table 2).
Isolates with reduced fluconazole susceptibility
By sequencing, all but one isolate (from patient 2; Table
2) contained at least one missense mutation when com-
pared with the C. albicans ATCC 28526 sequence (Gen-
Bank accession no. AF153844) (results not shown).
Results obtained by the RCA assay were concordant with
DNA sequencing for all isolates. However, DNA sequenc-
ing identified four additional amino acid substitutions
(D153E, F126L, K108E and a novel substitution G450V)
in six separate isolates (from patients 5, 6, 10, 11 and 12
as shown in Table 3) – these substitutions were not
detected by RCA as the corresponding padlock probes tar-
Sensitivity of the RCA assay in the presence of DNA mixturesFigure 3
Sensitivity of the RCA assay in the presence of DNA mixtures. The accumulation of double-stranded DNA was 
detected by staining with Sybr green I. RCA signals indicative of the presence of a specific mutation are shown as exponential 
increases in fluorescence signal above baseline. The figure illustrates the padlock probe-RCA reaction using the Ca-Y257H-spe-
cific probe to detect varying concentrations (100%, 50%, 20%, 10% and 5%) of target template (1011copies). The target tem-
plate was DNA from isolate C594 containing the Y257H mutation; this was diluted with DNA from strain ATCC 10231 
(without the Y257H mutation). The intensity of RCA fluorescence signal weakened with decreased template concentration. 
The sensitivity of the assay corresponded to a concentration of 5% template DNA in the mixture.Page 6 of 12
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Thus ERG11 point mutations resulting in 16 different
amino acid substitutions were detected among the 25 test
isolates by RCA (Table 2) whereas 20 substitutions were
identified by DNA sequencing. Sequencing identified that
all amino acid substitutions were due to homozygous
nucleotide polymorphisms.
The substitution G464S was present in four isolates,
G448E and G307S were present in three isolates each and
the substitutions Y132H, S405F and R467K (each n = 1)
were rare (Table 2). Of note, five of the 10 ERG11 muta-
tions (leading to amino acid substitutions A61V, G450E,
H238R, R467I and Y257H) present in "reference" isolates
from the United States (Table 1) were not detected in Aus-
tralian isolates. Overall, the most frequently-identified
substitutions were E266D (n = 11 isolates) followed by
V488I (n = 8), D116E (n = 8) and K128T (n = 7). Nineteen
of the 20 mutations (95%) were clustered in three regions
of Erg11p: positions 105–165, 266–287 and 405–488
(Table 2).
Specificity of the RCA assayFigure 4
Specificity of the RCA assay. RCA results monitored by the RotorGene 6000 real-time PCR machine (Corbett research). 
The accumulation of double-stranded DNA was detected by staining with Sybr Green I. RCA signals indicating the presence of 
the mutation of interest ((labeled as "positive signal") are shown as exponential increases in fluorescence. The experiment was 
conducted using the Ca-Y132H-specific RCA probe and tested on eight C. albicans isolates with known ERG11 mutation sites 
(Table 1). Ligation-mediated RCA with matched templates (DNA from isolates C527, C594, C507) containing the targeted 
SNPs produced "positive signals". Other templates showed an absence of signal (labeled as "negative signal").
Table 3: Additional amino acid substitutions identified by ERG11 sequencing in five C. albicans isolates with reduced susceptibility to 
fluconazole.
Patient/isolate no. Substitutions detected by RCA Substitutions detected by DNA sequencing
5 G307S G307S, G450V
6-Aa E266D E266D, D153E
6-Ba D116E D116E, D153E
10 E266D, V488I, S405F, Y132H E266D, V488I, S405F, Y132H, K108E
11 E266D, V437I E266D, V437I, F126L
12-Aa G464S G464S, K108E
a The "A" and "B" notation of patient numbers refers to isolates which were cultured sequentially from the same patient at different times.Page 7 of 12
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(patients 3 6, 8, 12 and 16). Isolates from patients 3 and
8 had similar ERG11 mutation and MIC profiles; how-
ever, isolates from patient 16 demonstrated a step-wise
increase in voriconazole MICs in parallel with additional
amino acid substitutions; the isolate with the highest MIC
contained five substitutions while the isolate with the
lowest MIC contained three (Table 2). Conversely, for
patient 12, one additional mutation was present from the
analysis of the second isolate (isolate 12B; see also Table
3) but the fluconazole and voriconazole MICs of this iso-
late were lower than that for isolate 12A. Both isolates
from patient 6 had similar azole MICs but had one differ-
ent ERG11 mutation (Tables 2 and Table 3).
Fluconazole-susceptible isolates
No ERG11 mutations were detected by either RCA or
ERG11 sequencing in five of the 23 (22%) fluconazole-
susceptible isolates. In the other 18, five amino acid sub-
stitutions namely E266D (n = 15 isolates), D116E (n =
11), V488I (n = 7), K128T (n = 3) and V437I (n = 2) were
identified (Table 2). By sequencing, homozygous nucle-
otide changes that led to the E266 substitution were
present in all isolates; for the remaining amino acid sub-
stitutions, nucleotide mutations were heterozygous. In all
cases, RCA results were concordant with those obtained
by DNA sequencing confirming that the RCA-based assay
is capable of detecting both homozygous and hetero-
zygous SNP substitutions in ERG11.
Mutations unique to isolates with reduced fluconazole 
susceptibility
Fifteen of the 20 Erg11p amino acid substitutions present
in C. albicans isolates displaying S-DD susceptibility or
resistance to fluconazole were not identified in flucona-
zole-susceptible strains (Table 2). These included the sub-
stitutions G307S, G464S, G448E R467K, S405F and
Y132H which have been reported to result in reduced sus-
ceptibility to azoles [5,10,15]
Discussion
Azole antifungals are widely used for therapy and proph-
ylaxis of Candida infections. A better understanding of the
mechanisms of resistance to these agents as well as early
detection of resistance are essential for patient manage-
ment. Azole resistance is often due to a combination of
factors including increased expression of efflux pumps
and missense mutations in ERG11 [3-5,15]. The latter
have been linked to clinically-relevant increases in the
MICs, not only to fluconazole, but also to the newer
azoles voriconazole and posaconazole [4,5,10,15] This
proof of principle study highlights the great potential of a
simple rapid (2 h) and highly-specific RCA-based SNP
detection assay that can be readily be performed in the
clinical laboratory for the detection and/or surveillance
for ERG11 mutations. Using this method, we identified
Erg11p amino acid substitutions in 24 of 25 previously-
uncharacterised Australian isolates with reduced suscepti-
bility to fluconazole.
The sensitivity and reproducibility of the RCA assay was
established by determining its ability to detect known
ERG11 mutations in "reference" isolates (Table 1) in com-
parison with DNA sequencing. The padlock probes
designed for this study also accurately identified and dis-
tinguished between SNPs within the ERG11 genes in the
test isolates. These included SNPs that were located close
together such as those at nucleotides 1343, 1346 and
1349 corresponding to the amino acid substitutions
G448E, F449S and G450E, respectively (Additional file
1). Importantly, identification of ERG11 mutations by the
RCA assay was concordant with sequencing in all cases
where an ERG11 mutation-specific probe was used. An
additional finding was that even though probes (or pairs
of probes) were not designed to detect heterozygous
nucleotide substitutions per se, the RCA assay detected
such changes in isolates containing an ERG11 mutation in
only one allele, as demonstrated by their identification in
fluconazole-susceptible isolates.
A large number (n = 20) of amino acid substitutions were
identified in test isolates with reduced susceptibility/
resistance to fluconazole. In agreement with a prior
report, all but one isolate had at least one, and often mul-
tiple missense mutations in ERG11 [15]. Substitutions
also varied widely between individual isolates. Similar
results have been reported by Perea et al. who detected 13
ERG11 mutations in 20 C. albicans isolates with high level
fluconazole resistance of which 11 were linked to resist-
ance [5]. In contrast, just a single ERG11 mutation profile
(comprising the same two mutations) was found in 14 of
15 fluconazole-resistant isolates in another study [17].
To our knowledge the G450V amino acid substitution has
not been previously identified among isolates with
reduced susceptibility to azoles. Most of the other substi-
tutions described here have previously been seen in azole-
resistant isolates [5,15,17,20] In particular, the substitu-
tions G464S, G307S and G448E, known to confer azole
resistance [5,12,15], were identified in three or more iso-
lates. However, it is notable that the substitutions Y132H,
S405F and R467K which appear to be prevalent in the
United States and Europe were rare in Australian isolates
[5,12,13,15]. Nineteen of the 20 amino acid substitu-
tions, including G450V, present in the test isolates were
clustered into the three "hot-spot" regions as described
previously [19]. These hot spots include the residues 105–
165 near the N-terminus of the protein, region 266–287
and region 405–488 located towards the C terminus of
the protein. The exception was the G307S substitution (nPage 8 of 12
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Erg11p, G307S is located close to the heme cofactor bind-
ing site. As such, substitutions at this residue might be
expected to impact negatively on the binding of the azole
[28].
In contrast to the fluconazole-resistant strains described
above, 22% of fluconazole-susceptible isolates contained
no ERG11 mutations and of those that did, substantially
fewer (five compared with 20) amino acid substitutions
were detected. Also of interest, all Erg11p amino acid sub-
stitutions from isolates with reduced azole susceptibility
phenotypes were homozygous whereas with one excep-
tion (E266D), those in fluconazole-susceptible isolates
were present as heterozygous substitutions. While these
two observations support the general notion that ERG11
mutations are linked to azole resistance, the presence of
ERG11 mutations in susceptible isolates is not readily
explained. Development of "resistance" requires pro-
longed exposure to an azole [3,4]; however previous stud-
ies have not attempted to relate mutations in susceptible
isolates to fluconazole exposure. Due to the retrospective
nature of the present study we were unable to test this
association.
The limitations of this study are recognised. Given the
small numbers of isolates in our collection and that the
presence of ERG11 mutations are not necessarily func-
tionally related to resistance, we were unable to determine
the clinical relevance of the ERG11 mutations identified.
Since the substitutions E266D, D116E and V347I were
present in both fluconazole-susceptible and, resistant iso-
lates, it could be argued that they are unlikely to have con-
tributed to reduced azole susceptibility [5,12,17,19]. On
the other hand, with one exception, all identified muta-
tions were heterozygous in fluconazole-susceptible iso-
lates; the finding supports the contention that loss of
heterozygosity in a diploid species such as C. albicans is a
step in the development of the azole-resistant phenotype
[3,20,29]. It is also possible that many ERG11 polymor-
phisms whilst not conferring resistance per se, may play a
role in increasing the level of resistance [12,21].
Conversely, the absence of substitutions G307S, G448E,
G464S, Y132H, S405F and R467K, in susceptible isolates
strongly suggests they have contributed to the resistant
phenotype. This hypothesis can be tested by site-directed
mutagenesis and expression studies of specific ERG11
alleles in Saccharomyces cerevisiae. Using this approach,
Sanglard and co-workers demonstrated that the substitu-
tions G464S, Y132H, S405F and R467K were linked to
azole resistance among their collection of isolates [12];
similar studies are warranted to determine if the new sub-
stitution G450V is associated with resistance. Testing
matched, susceptible and resistant, isolates from the same
patient for ERG11 mutations may also assist in determin-
ing if particular mutations impact on azole resistance;
unfortunately, matched isolates were not available in the
present study. In general, neither the type or number of
mutations in isolates sequentially obtained from the same
patient correlated with azole MICs (Table 2), emphasising
the need to assess additional genes to understand the con-
tribution of each to the resistance phenotype. As such,
methods that detect polymorphisms are well-placed to
screen large numbers of isolates from different sources for
mutations and to guide functional testing of these isolates
for resistance.
This study demonstrates a new application of a simple
RCA-based technique for the rapid and accurate detection
of SNPs in the ERG11 gene as potential markers of resist-
ance and for the tracking of resistant strains. Other
sequencing-independent methods include conventional
real time PCR and/or other probe-based technologies eg.
molecular beacons or TaqMan probes [30,31]. Results
using conventional real time PCR are well-known to be
highly-dependent on the physical characteristics of the
platform. Molecular beacons and TaqMan probe methods
are conveniently available in the form of commercial kits.
Although able to detect SNPs with good sensitivity
[30,31], strict attention to the Tm of the probes is required
to ensure adequate specificity. The RCA-based method
described here offers several advantages over other ampli-
fication techniques in that ligation of the probe ends by
DNA ligase requires perfectly-matched target-probe com-
plexes preventing nonspecific amplification generated by
conventional PCR and resulting in very high specificity. It
is also rapid (2 h compared to 1–2 days for DNA sequenc-
ing following DNA extraction). Whilst the set-up costs of
the assay are relatively high, (AUD 300 per probe), a typ-
ical commercial batch of each probe provides sufficient
material for up to 5000 assays. Running costs are esti-
mated at no more than AUD 2 per assay compared to
AUD 15 for DNA sequencing. The limitations of RCA in
the primary identification of resistance are acknowledged
(see above). However, the technique is well-suited as an
epidemiological tool for high throughput screening for
commonly-encountered ERG11 SNPs to assist in the
detection of potentially-resistant strains and to track the
movement of such strains. Further, its utility in detecting
SNPs in other genes that have been linked to azole resist-
ance in C. albcians such as those encoding for the tran-
scriptional activator of CDR1 (TAC1) and the
transcriptional activator Upc2 (UPC2) [32,33] warrant
consideration.
Conclusion
In conclusion, the sensitive and specific RCA-based assay
proved to be a simple robust method for the rapid detec-
tion of ERG11 mutations and showed excellent concord-Page 9 of 12
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for tracking specific strains and identifying markers/co-
markers of azole resistance. Broader implications include
application of the method in the study of oher gene muta-
tions linked to azole resistance in C. albicans and of azole
resistance in other fungi such as Aspergillus fumigatus in




Eight fluconazole-resistant "reference" isolates with previ-
ously-described mutations in ERG11 (strains C438, C440,
C470, C480, C507, C527, C577 and C594 provided by A.
Chau, Schering-Plough Research Institute, Kenilworth,
New Jersey; Table 1) [15] were used to validate the RCA
assay. Two fluconazole-susceptible isolates (strains ATCC
10231 and ATCC 90028) were purchased from the Amer-
ican type culture collection (ATCC; Rockville, Md). Of 46
Australian clinical C. albicans isolates, 25 (obtained from
19 patients) were resistant, or had reduced susceptibility
to fluconazole (five patients – patient 3, 6, 8, 12 and 16
had >1 isolate recovered on separate occasions) and 21
were fluconazole-susceptible (Table 2). These isolates
were from the culture collection of the Clinical Mycology
laboratory, Westmead Hospital, Sydney and the Mycology
Unit, Women's and Children's Hospital, Adelaide. The
experimental work was approved as part of a Centre of
Clinical Research Excellence Grant awarded by the
National Health and Medical Research Council of Aus-
tralia (grant #264625) and approved by the Scientific
Advisory Committee, Sydney West Area Health Service
and the Research and Development Committee, Centre
for Infectious Diseases and Microbiology Laboratory Serv-
ices, Westmead Hospital. Thus, 33 isolates with reduced
fluconazole susceptibility and 23 fluconazole-susceptible
isolates were studied. Isolates were identified as C. albicans
by standard phenotypic methods [36] and maintained on
Sabouraud's dextrose agar at 4°C until required.
Broth microdilution susceptibility testing
MICs of fluconazole and voriconazole (Pfizer Australia,
Ryde, Australia) were determined for the ATCC and Aus-
tralian study isolates (total n = 48) by broth microdilution
using the Clinical and Laboratory Standards Institute
(CLSI) M27-A2 protocol for susceptibility testing of yeasts
[37]. Candida parapsilosis ATCC 22019 and Candida krusei
ATCC 6528 were the quality control strains for each test
run. The MIC endpoint was the lowest concentration of
drug resulting in 50% growth inhibition compared with
growth in the control (drug-free) well. Isolates were cate-
gorised as susceptible (MIC ≤ 8 μg/ml), susceptible dose-
dependent (S-DD; MIC 16–32 μg/ml) or resistant (MIC ≥
64 μg/ml) to fluconazole according to CLSI methodology
[37]. Fluconazole and voriconazole MICs for the "refer-
ence isolates" have been reported [15] (Table 1).
DNA extraction and PCR amplification of the ERG11 gene
DNA extraction was performed as described previously
[38]. The near-full length ERG11 gene (1480 bp) was
amplified with primers ERG11-S (5' aggggttccatttgtttaca
3') and ERG11-A (5' ccaaatgatttctgctggtt 3'; Beijing
AUGCT Biotechnology Co. Ltd., Beijing, China) prepara-
tory to hybridization with padlock probes and subsequent
RCA (all isolates; see below) and for ERG11 sequence
analysis (ATCC and Australian isolates).
Each PCR reaction contained: 1.5 μl (12–15 ng/μl) tem-
plate DNA, 0.25 μl (50 pmol/μl) each of forward primer
and reverse primer, 1.25 μl dNTPs (2.5 mM of each dNTP;
[Roche Diagnostics, Mannheim, Germany]), 0.1 μl Hot-
Star Taq polymerase (5 units/μl), 2.5 μl 10 × PCR buffer,
(Qiagen, Doncaster, Victoria, Australia) and water to a
total volume of 25 μl. Amplification was performed on a
Mastercycler gradient thermocycler (Eppendorf AG, North
Ryde, Australia). The thermal cycling conditions were
95°C for 15 min, followed by 35 cycles of 94°C for 45 s,
58°C for 45 s, and 72°C for 90 s, with a final extension
step at 72°C for 10 min. PCR product was visualised
under UV illumination to verify amplicon quantity prior
to sequence analysis or RCA.
ERG11 sequence analysis
PCR products were purified using the PCR Product Pre-
sequencing Kit (USB Corporation, Cleveland, Ohio USA)
and sequenced using ERG11-S and ERG11-A primers, and
the BigDye Terminator (version 3.1) cycle sequencing kit
in the ABI PRISM 3100 genetic analyser (Applied Biosys-
tems, Foster City, CA). Sequences were entered into a
BLASTn sequence analysis search and analyzed using edit-
ing and analyses programs in the BioManager (ANGIS)
facility (accessed via. http://angis.org.au/).
Primer and padlock probe design
The ERG11 sequence of the azole-susceptible strain C.
albicans ATCC 28526 as published by Marichal et al. (Gen-
Bank database accession no. AF153844) was used for
probe design. This sequence was chosen because C. albi-
cans ATCC 28526 has been extensively characterised. A
total of 24 padlock probes targeting 24 different ERG11
mutation sites were designed (Additional file 1). Ten of
the 24 probes were designed to detect 10 mutations
present in the "reference" isolates (Table 1); the remaining
14 targeted additional ERG11 mutations which have been
identified in azole-resistant isolates [5,10,15,19].
The probes were 106–123 nucleotides (nt) in length, con-
sisting of two adjacent target complementary sequences
with a 48 nt linker region (Figure 1). To optimise binding
to target DNA, probes were designed with a minimum of
secondary structure and with a Tm of the 5'-end probe
binding arm greater than the temperature used for probe
ligation (62°C; see below). To increase the specificity, thePage 10 of 12
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below the ligation temperature [25]. In particular, careful
attention was paid to the linker region for each point
mutation-specific probe to (i) minimise similarity to
those mutations closely-located to the mutation of inter-
est and (ii) to allow primer binding during RCA and
amplification of the probe-specific signal. The 2 primers
used for RCA – RCA primer 1 (5' ATGGGCACCGAA-
GAAGCA 3', Tm 55°C) and RCA primer 2 (5' CGCGCA-
GACACGATA 3', Tm 55°C) – were designed to specifically
bind the linker region of the probes (Additional file 1)
Purification of RCA template
Prior to ligation of the probe, ERG11 PCR products were
purified to remove excess buffer, dNTP and primers: 25 μl
of the PCR product was added to a well of a Millipore PCR
purification plate (Pall Life Sciences, Ann Arbor, MI, USA)
which was then placed on a vacuum manifold for 10–20
min to draw fluid and small particles through the mem-
brane, leaving DNA on top of the membrane. A further 25
μl of dH2O was added to the well and the process
repeated. The plate was removed from the vacuum, 20 μl
of dH2O was added and the mixture incubated at 25°C for
2 min before transferring to a clean Eppendorf tube. Puri-
fied PCR products were stored at 4°C.
Ligation of padlock probe and exonucleolysis
Purified amplified PCR product (1011 copy numbers of
DNA template [DNA calculator; http://www.uri.edu/
research/gsc/resources/cndna.html]) was mixed with 2 U
of Pfu DNA ligase (Stratagene, La Jolla, CA, USA) and 0.1
μM padlock probe as previously described [25] and sub-
jected to multiple cycle ligation comprising one cycle of
denaturation at 94°C for 5 min, followed by five cycles at
94°C for 30 s and 4 min of ligation at 62°C. Exonucleol-
ysis was then performed to remove unligated probe and
template PCR product; the purpose of the last step is to
reduce subsequent ligation-independent amplification
events during RCA. It was performed in 20-μl volumes by
adding 10 U each of exonuclease I and exonuclease III
(New England Biolabs, UK) to the ligation mixture and
incubating at 37°C for 60 min followed by 95°C for 3
min.
RCA
After exonucleolysis, RCA reactions was performed in 50
μl volumes containing 8 U of Bst DNA polymerase (New
England Biolabs), 400 μM deoxynucleotide triphosphate
mix, 10 pmol of each RCA primer, 5% of dimethyl sulfox-
ide (v/v) and 10 × SYBR Green I (Sigma-Aldrich, Castle
Hill, Australia). Probe signals were amplified by incuba-
tion at 65°C for 30 min and the accumulation of dsDNA
products were monitored using a Corbett RotorGeneTM
6000 real-time PCR machine (Corbett Research, Mortlake,
Australia). Probe signals were also visualised on a 1.5%
agarose gel to verify the specificity of probe-template
binding.
Nucleotide sequence accession numbers
The ERG11 sequences of the study isolates have been
deposited in the GenBank database with the following
accession numbers: FJ159508, FJ159444 to FJ159507
inclusive and FJ232378 to FJ232396 inclusive.
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